Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis
暂无分享,去创建一个
I. Poon | A. Louie | A. Sahgal | E. Atenafu | U. Ricardi | K. Redmond | M. Foote | T. Biswas | S. Badellino | R. Dagan | D. Erler | Y. Lee
[1] B. Yaremko,et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial , 2020, medRxiv.
[2] L. Collette,et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. , 2020, The Lancet. Oncology.
[3] A. Louie,et al. A Review of Ongoing Trials of Stereotactic Ablative Radiotherapy for Oligometastatic Cancers: Where Will the Evidence Lead? , 2019, Front. Oncol..
[4] Michael Lock,et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.
[5] J. Lee,et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Loo,et al. SABR-COMET: harbinger of a new cancer treatment paradigm , 2019, The Lancet.
[7] W. Tomé,et al. Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. , 2019, International journal of radiation oncology, biology, physics.
[8] M. Parmar,et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial , 2018, The Lancet.
[9] Joe Y. Chang,et al. Time to abandon single-site irradiation for inducing abscopal effects , 2018, Nature Reviews Clinical Oncology.
[10] E. Goetghebeur,et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Palma,et al. Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists , 2017, American journal of clinical oncology.
[12] F. Lohr,et al. A multinational report of technical factors on stereotactic body radiotherapy for oligometastases. , 2017, Future oncology.
[13] J. Lee,et al. Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.
[14] Charles Swanton,et al. Metastasis as an evolutionary process , 2016, Science.
[15] F. Lohr,et al. A multi-national report on stereotactic body radiotherapy for oligometastases: Patient selection and follow-up* , 2016, Acta oncologica.
[16] David A. Palma,et al. The oligometastatic state—separating truth from wishful thinking , 2014, Nature Reviews Clinical Oncology.
[17] A. Bezjak,et al. The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. , 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).
[18] P. Okunieff,et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. , 2012, International journal of radiation oncology, biology, physics.
[19] B. Nordlinger,et al. Long‐term survival following resection of colorectal hepatic metastases , 1997, The British journal of surgery.
[20] P. Iyengar,et al. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.
[21] M Buyse,et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. , 1997, The Journal of thoracic and cardiovascular surgery.